Attovia Therapeutics (NASDAQ:ATTO) Research Coverage Started at Morgan Stanley

Morgan Stanley initiated coverage on shares of Attovia Therapeutics (NASDAQ:ATTO) in a research note issued to investors on Monday morning, Marketbeat reports. The brokerage issued an overweight rating and a $39.00 target price on the stock.

Attovia Therapeutics Trading Up 4.1%

ATTO stock opened at $23.13 on Monday. Attovia Therapeutics has a 12 month low of $16.15 and a 12 month high of $24.32.

Attovia Therapeutics (NASDAQ:ATTO) last released its quarterly earnings data on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter.

Insider Buying and Selling

In other news, major shareholder Life Sciences Xi L.P. Frazier acquired 588,235 shares of Attovia Therapeutics stock in a transaction on Thursday, August 6th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the acquisition, the insider directly owned 6,154,213 shares of the company’s stock, valued at $104,621,621. This trade represents a 10.57% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Redmile Group, Llc bought 400,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, with a total value of $6,800,000.00. Following the completion of the transaction, the insider owned 1,182,854 shares in the company, valued at $20,108,518. This represents a 51.10% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 2,740,587 shares of company stock valued at $47,269,979 over the last 90 days. 0.99% of the stock is owned by insiders.

Key Headlines Impacting Attovia Therapeutics

Here are the key news stories impacting Attovia Therapeutics this week:

• Positive Sentiment: Positive ATTO-1310 clinical update: Attovia reported preliminary proof of concept for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. Complete Phase 1b data are expected in the fourth quarter of 2026, providing a near-term catalyst. Attovia Therapeutics second-quarter results and corporate update
• Positive Sentiment: New bullish analyst coverage: LifeSci Capital initiated coverage with an “outperform” recommendation. Citigroup, Leerink Partners and Royal Bank of Canada also began coverage, increasing institutional visibility around the biotech. LifeSci Capital coverage
• Positive Sentiment: Royal Bank of Canada recently upgraded Attovia to “moderate buy,” reinforcing the positive analyst sentiment surrounding the company’s pipeline. Royal Bank of Canada upgrade
• Neutral Sentiment: Attovia’s second-quarter earnings release provides investors with an updated financial and corporate overview, with attention likely focused on development spending and the company’s ability to fund upcoming clinical work. Attovia Therapeutics earnings press release
• Negative Sentiment: Widening quarterly loss: Attovia reported a second-quarter loss of $4.88 per share, while separate coverage characterized the company’s net loss as wider than in the prior-year period. Continued losses could weigh on the stock if investors become concerned about cash needs or execution risk. Attovia Therapeutics Q2 net loss

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.